BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34981443)

  • 1. Hepatocellular carcinoma diagnosis using a novel electrochemiluminescence immunoassay targeting serum IgM-free AIM.
    Shimizu T; Sawada T; Asai T; Kanetsuki Y; Hirota J; Moriguchi M; Nakajima T; Miyazaki T; Okanoue T
    Clin J Gastroenterol; 2022 Feb; 15(1):41-51. PubMed ID: 34981443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
    Koyama N; Yamazaki T; Kanetsuki Y; Hirota J; Asai T; Mitsumoto Y; Mizuno M; Shima T; Kanbara Y; Arai S; Miyazaki T; Okanoue T
    J Gastroenterol; 2018 Jun; 53(6):770-779. PubMed ID: 29086016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
    Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma.
    Tanaka T; Taniguchi T; Sannomiya K; Takenaka H; Tomonari T; Okamoto K; Kitamura S; Okahisa T; Tamaki K; Mikasa H; Suzuki S; Takayama T
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1348-55. PubMed ID: 23432345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
    Nomura F; Ishijima M; Kuwa K; Tanaka N; Nakai T; Ohnishi K
    Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
    Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
    BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma in young morbid obese patients with non-alcoholic fatty liver disease.
    Tobari M; Hashimoto E; Taniai M; Nishino T; Tokushige K
    Clin J Gastroenterol; 2020 Dec; 13(6):1289-1296. PubMed ID: 32880022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of immunoglobulin M-free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Okanoue T; Yamaguchi K; Shima T; Mitsumoto Y; Mizuno M; Katayama T; Seko Y; Moriguchi M; Umemura A; Itoh Y; Miyazaki T
    Hepatol Res; 2022 Dec; 52(12):998-1008. PubMed ID: 35939571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
    Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I
    Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
    Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
    Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
    Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
    PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
    Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
    BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
    Aby E; Phan J; Truong E; Grotts J; Saab S
    J Clin Gastroenterol; 2019 Feb; 53(2):142-146. PubMed ID: 29912761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C.
    Tokushige K; Hashimoto E; Yatsuji S; Tobari M; Taniai M; Torii N; Shiratori K
    J Gastroenterol; 2010 Sep; 45(9):960-7. PubMed ID: 20376504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review.
    Shahini E; Pasculli G; Solimando AG; Tiribelli C; Cozzolongo R; Giannelli G
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
    Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
    PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
    Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
    Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
    Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
    Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
    Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.